Merck

Margie McGlynn, president of Merck Vaccines and Infectious Diseases, has resigned effective November 1st. Amy Rose, a spokeswoman for the company, commented, “She has professional and personal aspirations she’d like to pursue.” A replacement has not yet been named.

Ms. McGlynn oversaw the launch of Gardasil cervical cancer vaccine, Rotateq rotavirus vaccine and Zostavax shingles vaccine, among other products. She spent 26 years with the company and previously helped run U.S. commercial operations.

Merck is expected to complete its $41 billion acquisition of Schering-Plough by the end of the year. According to Ms. Rose, the company will announce the members of the executive committee of the combined Merck/Schering-Plough, and senior management, as the close of the merger nears.

Sign up today for Contracting & Outsourcing 2009!